Haleon Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Haleon şirketinin toplam hissedar öz sermayesi £16.7B ve toplam borcu £9.1B olup, bu da borç-öz sermaye oranını 54.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £33.4B ve £16.7B dir. Haleon 'in FAVÖK'ü £2.5B faiz karşılama oranı 6.9 dur. Şirketin £531.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

54.2%

Borç/özkaynak oranı

UK£9.05b

Borç

Faiz karşılama oranı	6.9x
Nakit	UK£531.00m
Eşitlik	UK£16.71b
Toplam yükümlülükler	UK£16.69b
Toplam varlıklar	UK£33.40b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HLN 'nin kısa vadeli varlıkları ( £4.7B ) kısa vadeli yükümlülüklerini ( £5.6B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: HLN 'un kısa vadeli varlıkları ( £4.7B ) uzun vadeli yükümlülüklerini ( £11.1B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HLN 'nin net borç/öz sermaye oranı ( 51% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: HLN şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Borç Kapsamı: HLN 'nin borcu işletme nakit akışı ( 24.2% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: HLN 'in borcuna ilişkin faiz ödemeleri EBIT ( 6.9 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Haleon Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Haleon: Tailwinds Are Mostly Priced In

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 455,701,825 shares, representing 4.99% of its issued share capital., under the authorization approved on May 8, 2024.

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Dr. Reddy'S Laboratories S.A. completed the acquisition of Northstar Switzerland SARL from Haleon plc (LSE:HLN).

Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription

Haleon: Defensive Consumer Healthcare Stock As Safe Haven

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025

Dr. Reddy'S Laboratories S.A. signed a definitive agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Haleon plc Announces Directorate Change

Haleon plc Announces Chief Financial Officer Changes

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Sensodyne Introduces New Triple Action Formula: 'Sensitivity Gum & Enamel'

Haleon plc, Annual General Meeting, May 08, 2024

Haleon plc Proposes Final Dividend for Fiscal Year 2023, Payable on 16 May 2024

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

The Investment Case For Haleon: Steady Shareholder Value Accumulation

Haleon plc to Report Fiscal Year 2023 Results on Feb 29, 2024

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon Reportedly Exploring Sale of Nicotine Gum Business

Haleon: A Hidden Gem In The Consumer Health Market

Haleon exploring sale of ChapStick Brand - report

Haleon plc Announces Board Changes

Haleon said to evaluate potential deals to increase its size - report

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon: Undervalued With Clear Catalyst Ahead

Former GSK consumer health unit Haleon hits all-time low

Haleon Introduces Advil PLUS Acetaminophen to Canadians, Combining Two Trusted Pain Relievers into One Convenient Tablet

Haleon plc to Report First Half, 2022 Results on Sep 19, 2022

Haleon CEO says brand recognition, gross margins will drive growth - CNBC

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin